2025

1. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

   Blood Advances, Vol. 9, Núm. 16, pp. 4248-4259

2. CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

   JTO Clinical and Research Reports, Vol. 6, Núm. 8